Obinutuzumab for fibrillary glomerulonephritis
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with fibrillary glomerulonephritis through a kidney biopsy.
- You have at least 1 gram of protein in your urine per day.
- Your kidney function (eGFR) is 20 mL/min/BSA or higher.
- You have no other reason for kidney disease (like diabetes or an autoimmune condition).
- You have not taken certain medications recently (like rituximab, cyclophosphamide, or high-dose prednisone).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This study tests a new drug called obinutuzumab to see if it can keep nephrotic syndrome from coming back in adults who need repeated rituximab treatments. The goal is to see if obinutuzumab works better at controlling the disease compared to current care.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This study is testing a drug called obinutuzumab to see if it can lower PLA2R antibodies in people with membranous nephropathy (a kidney disease). The goal is to reduce protein leakage in urine and improve kidney health.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
Hear when a new Fibrillary Glomerulonephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.